Karyopharm Therapeutics share price logo

Karyopharm Therapeutics

NASDAQ: KPTI

$1.87

-0.07

(-3.61%)

as on

Karyopharm Therapeutics Stock Performance

as on August 31, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $1.86
    $1.98
    downward going graph

    0.53%

    Downside

    5.88%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.79
    $10.99
    downward going graph

    4.28%

    Downside

    487.70%

    Upside

    downward going graph

Karyopharm Therapeutics share price movements today

Previous Close
$1.94
Open
$1.98
Volume
1.2M
Market Cap
$42.4M
Day's Low - High
$1.86 - $1.98
52 Week Low - High
$1.79 - $10.99

Karyopharm Therapeutics Historical Returns

1 Month Return
-2.6 %
3 Month Return
-79.45 %
1 Year Return
-73.7 %
3 Year Return
-90.26 %
5 Year Return
-97.85 %

Karyopharm Therapeutics Stock Fundamentals & Key Indicators

Check Karyopharm Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$42.4M

EPS (TTM)

-5.845

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

-0.15

EBITDA

-82.2M

Revenue (TTM)

146.6M

Profit Margin

-153.28%

Return On Equity TTM

-891.05%

Karyopharm Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Karyopharm Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$42.4M-97.85%NA-153.28%NA
BUY$44.6B614.61%NA0.00%NA
BUY$137.2B170.45%31.9286.04%NA
BUY$55.1B-63.37%-7.98-12.57%NA
BUY$85.8B17.94%19.984.86%0.44%

Stock Returns calculator for Karyopharm Therapeutics Stock including INR - Dollar returns

The Karyopharm Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Karyopharm Therapeutics investment value today

Current value as on today

₹28,438

Returns

-₹71,562

(-71.56%)

Returns from Karyopharm Therapeutics Stock

-₹73,699 (-73.7%)

Dollar Impact

₹2,137 (+2.14%)

Analyst Recommendation on Karyopharm Therapeutics Stock

Based on 5 analysts

BUY

60.00%

Buy

40.00%

Hold

0.00%

Sell

Based on 5 analysts, 60% of analysts recommend a 'BUY' rating for Karyopharm Therapeutics. Average target price of $7.25

Karyopharm Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Karyopharm Therapeutics.

What analysts predicted

74.21%UPSIDE

Target Price

$7.25

Current Price

$1.87

Analyzed by

5 Analysts

Target

$7.25

Karyopharm Therapeutics target price $7.25, a slight upside of 74.21% compared to current price of $1.87. According to 5 analysts rating.

Indian Investors' Interest in Karyopharm Therapeutics Stock

Search interest for Karyopharm Therapeutics Stock has increased by 1203% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:1203% versus previous 30 day period

Karyopharm Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
33
42
38
30
30
37
44
34
35
33
Gross Profit
31
41
37
29
28
36
41
32
33
32
Operating Income
-33
-28
-26
-31
-33
-24
-15
-17
-26
-22
EBITDA
-31
32
-20
-19
-12
-25
-22
-89
-9
-53
Interest Expense
5
8
11
11
10
11
11
12
12
13
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-37
23
-32
-30
-23
-37
-33
-102
-22
-67
Income Tax Expense
0
0
0
0
0
0
0
0
0
-
Net Income
-37
23
-32
-30
-23
-37
-33
-102
-22
-67
Net Profit Margin
-112.79%
55.61%
-82.70%
-100.78%
-78.17%
-98.22%
-75.21%
-299.89%
-63.86%
-200.48%

Karyopharm Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
1
30
40
108
209
157
146
145
146
Gross Profit
0
1
-131
38
105
206
151
141
139
140
Operating Income
-110
-130
-179
-189
-171
-98
-142
-129
-119
-90
EBITDA
-110
-129
-175
-182
-167
-96
-139
-118
-38
-149
Interest Expense
1
1
2
15
27
26
24
23
37
45
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-109
-128
-178
-199
-195
-123
-164
-142
-76
-195
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-109
-128
-178
-199
-196
-124
-165
-143
-76
-196
Net Profit Margin
-71153.90%
-8036.39%
-588.10%
-488.08%
-181.59%
-59.14%
-105.23%
-97.99%
-52.62%
-134.21%

Karyopharm Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
23
-32
-30
-23
-37
-33
-102
-22
-67
Operating Cash Flow
-38
-19
-25
-38
-18
-5
-11
-22
-24
Investing Cash Flow
51
7
14
15
18
4
5
3
-10
Financing Cash Flow
40
-
0
-
0
-
29
49
0
Change in Cash
53
-11
-10
-23
0
-1
22
30
-35

Karyopharm Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-128
-178
-199
-196
-124
-165
-143
-76
-196
Operating Cash Flow
-73
-159
-190
-160
-107
-149
-92
-127
-75
Investing Cash Flow
17
-107
78
-53
141
-104
7
95
43
Financing Cash Flow
75
316
124
172
73
193
1
41
30
Change in Cash
19
49
11
-41
108
-60
-83
9
-1

Mutual Funds that own Karyopharm Therapeutics Stock

Check out the Mutual Funds with significant holdings in Karyopharm Therapeutics.

Funds
Holdings
Shares Held
MUTUAL FUND SERIES TRUST
4.959998%
1125000
T. ROWE PRICE SMALL-CAP VALUE FUND, INC.
3.864407%
876504
VANGUARD INDEX FUNDS
3.192964%
724211
Delaware Group Equity Funds IV
2.498366%
566666
TIAA-CREF Funds
1.776283%
402887

Global Institutional Holdings in Karyopharm Therapeutics

Funds
Holdings
Peter Kolchinsky
8.45%
Vanguard
4.73%
iShares
3.23%
Fidelity
0.77%
Invesco
0.36%

Karyopharm Therapeutics News & Key Events

    Insights on Karyopharm Therapeutics

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Moderna, Inc. Common Stock has given 472.8% return, outperforming this stock by 546.5%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Revolution Medicines, Inc. Common Stock has given 22.0% return, outperforming this stock by 112.3%

    • imgNEGATIVE IMPACT

      Price Dip

      img

      In the last 3 months, KPTI stock has moved down by -79.5%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 35.06M → 33.43M (in $), with an average decrease of 4.7% per quarter

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, -22.39M → -67.02M (in $), with an average decrease of 199.3% per quarter

    About Karyopharm Therapeutics

    Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
    OrganisationKaryopharm Therapeutics
    Headquarters85 Wells Avenue, Newton, MA, United States, 02459-3298
    IndustryBiotechnology
    CEOMr. Richard A. Paulson M.B.A.
    E-voting on sharesClick here to vote

    Key Management of Karyopharm Therapeutics

    Name

    Title

    Ms. Kristin Abate

    VP, Chief Accounting Officer & Assistant Treasurer

    Mr. Michael J. Mano J.D.

    Executive VP, Chief Legal Officer & Secretary

    Dr. Sharon Shacham M.B.A., Ph.D.

    Co-Founder & Chairman of Scientific Advisory Board

    Ms. Lori A. Macomber CPA

    EVP, CFO & Treasurer

    Mr. Brendan Twohig Strong

    Senior Vice President of Investor Relations

    Mr. James Accumanno J.D.

    Chief Compliance Officer

    Ms. Lisa DiPaolo

    Executive VP & Chief Human Resource Officer

    Mr. Richard A. Paulson M.B.A.

    President, CEO & Director

    Mr. Stuart Poulton

    Executive VP & Chief Development Officer

    Dr. Reshma Rangwala M.D., Ph.D.

    Executive VP, Chief Medical Officer & Head of Research

    FAQs

    What is Karyopharm Therapeutics share price today?

    Karyopharm Therapeutics share price today is $1.87 as on at the close of the market. Karyopharm Therapeutics share today touched a day high of $1.98 and a low of $1.86.

    What is the 52 week high and 52 week low for Karyopharm Therapeutics share?

    Karyopharm Therapeutics share touched a 52 week high of $10.99 on and a 52 week low of $1.79 on . Karyopharm Therapeutics stock price today i.e. is closed at $1.87,which is 82.98% down from its 52 week high and 4.47% up from its 52 week low.

    What is Karyopharm Therapeutics's market capitalisation today?

    Karyopharm Therapeutics market capitalisation is $0.00T as on .

    How to invest in Karyopharm Therapeutics Stock (KPTI) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Karyopharm Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Karyopharm Therapeutics Shares that will get you 0.8021 shares as per Karyopharm Therapeutics share price of $1.87 per share as on August 31, 2026 at 8:46 am IST.

    What is the minimum amount required to buy Karyopharm Therapeutics Stock (KPTI) from India?

    Indian investors can start investing in Karyopharm Therapeutics (KPTI) shares with as little as ₹95.152 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹951.52 in Karyopharm Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Karyopharm Therapeutics share’s latest price of $1.87 as on August 31, 2026 at 8:46 am IST, you will get 5.3476 shares of Karyopharm Therapeutics. Learn more about fractional shares .

    What are the returns that Karyopharm Therapeutics has given to Indian investors in the last 5 years?

    Karyopharm Therapeutics stock has given -97.85% share price returns and 30.75% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?